Search for Terms or Answers
Dr. Jack Cush reviews this week's news from RheumNow.com, including: placebo trumps controversial therapies, the dynamics of disease activity, fuse the big toe, and patients don’t appreciate being told “it's all in your head”!
The NEJM reports that retatrutide, an investigational incretin agent, was shown to yield up to 25% weight reduction, with subanalyses also showing reduced pain with knee osteoarthritis, and less apnea–hypopnea events in participants with obstructive sleep apnea.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Obesity is an incidental comorbidity in psoriatic arthritis (PsA). It is a modifiable, mechanistically active driver of disease onset, severity, and treatment failure. A new comprehensive review in RMD Open (Madsen et al., 2026) synthesizes 49 studies suggesting that weight management belongs in
That promised land of substantive weight loss comes within it the illusion of better disease control and, for inflammatory arthritis patients, the possibility of reducing the burden of regular medicines - often driven by the patient, with or without telling you. It is a dream worth aspiring to
Dr. Al Kim, St. Louis, discusses the effects of obesity on lupus activity, organ damage, complement levels and mTor activation.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
